Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Health Canada

- PMLiVE

Pioneering Paths: Women Leadership in Rare Disease

Rare diseases are often thought of as affecting one in 100,000 or one in 1,000,000 people, and that is true for some conditions. But there are many rare diseases that...

Medscape Education Global

- PMLiVE

Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies

The agreement gives Ipsen an option to receive exclusive global rights to two candidates

- PMLiVE

Ipsen announces launch of new UK headquarters in London life sciences community

The Paddington site will serve as one of the company’s three global hubs

- PMLiVE

Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate

STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio

- PMLiVE

Ipsen’s Cabometyx and BMS’ Opdivo recommended by NICE for advanced kidney cancer

The decision could benefit approximately 2,287 patients with renal cell carcinoma annually

- PMLiVE

Shortening the Journey at the Unusual Suspects Meeting

Medscape will be continuing their mission to shorten the diagnostic journey for patients with a rare disease at this year’s Unusual Suspects event on February 21.The Unusual Suspects is an...

Medscape Education Global

- PMLiVE

Ipsen’s Onivyde regimen granted FDA approval to treat pancreatic cancer

Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year

Rare Disease Diagnostic Odyssey

Medscape Education Global

- PMLiVE

Rare disease market access – Launching orphan drugs in secondary markets: the Nordic and MENA regions

Join us live at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February, to explore rare disease market access challenges and learn more about these high potential markets.

Mtech Access

- PMLiVE

We Can Shorten the Journey

During the shortest month of the year, Medscape Education is making a renewed commitment to use clinician education to help shorten the diagnostic and treatment journey for the millions of...

Medscape Education Global

- PMLiVE

Roche and Exelis/Ipsen’s drug combination shows promise in phase 3 prostate cancer study

Around 299,000 new cases of prostate cancer will be diagnosed in the US in 2024

- PMLiVE

BMS, Exelixis and Ipsen announce positive four-year results for kidney cancer regimen

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links